While more common than expected, the outlook for TP53 mutation carriers with sarcoma appears comparable to non-carriers, and options are emerging for cancer screening [10], family planning [25], and the selection of less carcinogenic cancer treatments. The gene discussed is TP53; the disease is cancer.